| I N TR ODU C TI ON
Chronic lymphocytic leukemia (CLL), the most common leukemia in adults, has a highly variable course, reflecting its biological heterogeneity. Many patients do not require treatment for years, whereas others exhibit aggressive disease, do not respond to treatment, and thus have a poor prognosis. Chromosomal abnormalities (including deletions of 11q, 13q or 17p (17p-), and trisomy 12) are present in about 80% of cases of CLL. Fluorescence in situ hybridization (FISH) is used to routinely screen for these chromosomal abnormalities. 1 Patients with 17p-CLL have the worst clinical outcomes, and the shortest progressionfree and overall survival (OS) times. 2 The 17p deletion is found in 10%
or less of patients with CLL but in up to 40% of relapsed or treatmentrefractory patients. Loss of the short arm of the chromosome 17
results from various chromosomal abnormalities, including unbalanced translocations, deletions, ring chromosomes and isochromosomes. 3 All these aberrations lead to the loss of one copy of the TP53 gene, and the remaining allele is mutated in most instances. Furthermore, 17p-is often associated with genomic complexity as detected with conventional karyotyping or genomic microarrays. 4, 5 The dismal prognosis for patients with 17p-CLL is mainly due to a lack of response to conventional treatments. In keeping with the role of TP53 as a pivotal regulator of the DNA response pathway, loss of this gene is associated with resistance to DNA-damaging agents (e.g., fludarabine and cyclophosphamide). Recently, new drugs targeting the B-cell receptor signaling pathway or the apoptosis machinery have shown efficacy in 17p-CLL, with a better treatment response and longer progression-free survival. [6] [7] [8] Despite good initial responses to these new targeted therapies, relapse can still occur -particularly in patients bearing a complex karyotype (K). 9 In contrast, some patients with de novo 17p-CLL have stable disease and remain asymptomatic for prolonged periods of time. 10, 11 All these observations underline the clinical heterogeneity of 17p-CLL. It has been shown that a number of clinical and biological markers (such as IGHV mutational status, the size of the 17p-clone, and genomic complexity) are significantly linked to the clinical outcome in the subgroup of patients with 17p-CLL.
12,13
The objectives of the present study of a series of 195 patients with 17p-CLL were to determine whether (i) the type of chromosomal abnormality leading to 17p loss (i.e., translocations, deletions, rings and isochromosomes, as identified by K analysis) was associated with the prognosis, and (ii) additional aberrations had an impact on the clinical outcome. To compare survival in patients in whom 17p-occurred before vs.
| M E TH ODS
after treatment, the time interval between the first documentation of 17p-and death or last follow-up was also evaluated.
All tests were two-sided, and the threshold for statistical significance was set to p 0.05. All statistical analyses were performed using MedCalc software (version 17.8.6, MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2017). patients with informative data. The protein p53 was dysfunctional in all 42 cases tested, including 2 patients in whom a TP53 mutation was not detected by NGS.
| R E SU LTS

| Characteristics of the study population
| Karyotyping and FISH data
Karyotyping and FISH results are summarized in Table 2 q10). Overall, der/dic(17;18) was the most frequent U-translocation (-17p) because it was present in 32 of the 195 patients (16%). The other frequent arm-to-arm translocations involved chromosomes 8q
(n 5 11, resulting in 8p deletion), 14q (n 5 6), 4q (n 5 4), 13q (n 5 4), and 21q (n 5 4). The remaining 64 U-translocations(-17p) (not arm-toarm) involved a wider variety of partners -most frequently chromosome 8 (n 5 15); this led to del8p (n 5 6), gain8q (n 5 6), or del8q (n 5 3) (Supporting Information Figure S1B ). The other 17p abnormalities were 17p deletion (n 5 45 out of 195, 23%), monosomy 17
(n 5 15, 8%), i(17q) (n 5 9, 5%) and ring chromosome 17 (n 5 4, 2%)
( Table 2 and Supporting Information Figure S1A ). Lastly, FISH showed that the percentage of cells with a TP53 deletion ranged from 3% to 100% (median: 70%). and 8q24 gain (HR 5 6.46, P < .0001). In a multivariate analysis, stage B/C and 8q24 gain remained significantly associated with shorter TFS (Table 3) .
For the study population as a whole, the median OS time from diagnosis was 179 months. In a univariate analysis, we found that age 65, Binet stage B/C, and unmutated IGHV status were associated with a significantly shorter median OS time (Table 3 , Supporting Information Figure S2 ). There were no significant statistical differences in the impact on OS between the different abnormalities leading to loss (Table 3) .
When comparing the survival time after the first documentation of 17p-, the patients who acquired this abnormality after treatment had a shorter OS time than those presenting with 17p-prior to treatment (HR 5 2.02, P 5 .03) (Supporting Information Figure S3 ).
| D I SCUSSION
To the best of our knowledge, the present study of 195 CLL patients with 17p-is the largest cohort in which the clinical significance of chromosome 17p abnormalities has been assessed in detail. In line with the literature data, we found that loss of the short arm of chromosome 17
is mainly due to unbalanced translocations (in 70% of cases), rather than 17p deletion, an isochromosome 17q or monosomy 17. 3, 16 Most of the U-translocations(-17p) (52%) were arm-to-arm events. In the remaining U-translocations(-17p), the breakpoints were mainly located in 17p11 or p12. In general (and regardless of the type of 17p abnormality), all or almost all of the 17p arm was lost. This supports the recent hypothesis whereby the effects of 17p deletion on tumor progression and treatment resistance might involve several genes and might not be solely due to TP53 loss. 17 The most frequent U-translocation(-17p) was dic/der(17;18), since it accounted for 16% of the study population. Woyach et al. suggested that dic(17;18) may correspond to the most aggressive subset of 17p-CLL cases. 18 We could not confirm this hypothesis; when compared with the other chromosomal abnormalities involving 17p in our large series, dic(17;18) did not have a significant impact on outcome.
In a univariate analysis, we found that monosomy 17 was significantly associated with a shorter TFS (relative to the other 17p abnormalities), and that isochromosome 17q was significantly associated with a shorter OS. Isochromosome 17q has been described as a frequent aberration (up to 33%) in small series of CLL cases with a TP53 deletion. 3, 19 A much lower incidence (4%) was observed in the present study. Moreover, i(17q) was significantly associated with trisomy 12 (44%, P 5 .03) and a larger clone 17p-size. In a recent study, CLL patients with i(17q) tended to have poorer OS than patients with other abnormalities affecting 17p13 -even though all the tested individuals were IGHV mutated. 20 In the present series, the IGHV genes were sequenced in only 2 of the 9 patients with i(17q); neither carried IGHV mutations. This finding shows that mutated IGHV status is not a constant feature in cases of i(17q). The present results corroborated the association between i(17q) status and a poor outcome because this defect was significantly correlated with shorter OS (P 5 .04). However, further studies are needed to establish whether i(17q) is an independent prognostic marker in 17p-CLL.
In accordance with previous reports, 12,21,22 we observed a shorter OS (calculated following the first documentation of 17p-) in patients having acquired the 17p-after treatment than in those with 17p-present before treatment. This finding might simply reflect the fact that patients with acquired 17p-have a more advanced disease but may also suggest that treatment selected a more aggressive clone with a growth advantage.
In contrast to other series, we did not observe a significant association between the percentage of cells with TP53 deletion and the clinical outcomes. In the literature, it has been reported that a low percentage of 17p-cells is associated with a more favorable outcome.
However, the optimal cut-off varied markedly from one study to another (from 10% to 80%) 10, 12, 23, 24 -indicating that this parameter is cohort-dependent and should not be taken into account when evaluating the prognosis of patients with CLL. Furthermore, several reports have documented the impact of small clones with disrupted TP53 genes on disease progression. 25, 26 Although only a small proportion of 17p-patients were analyzed,
we found that all the tested individuals had a dysfunctional p53 protein (including 2 cases without a TP53 mutation). These results highlight the importance of continuing to screen for 17p loss on a routine basis.
FISH is still the best technique for detecting TP53 deletion; its sensitivity threshold of about 5% is much lower than those obtained with innovative tools such as single nucleotide polymorphism arrays, multiplex ligation-dependent probe amplification and massively parallel sequencing.
We also looked at whether additional chromosomal abnormalities could influence the outcome. We confirm that a complex K is very frequent in 17p-CLL, since it was detected in 72% of our patients. 12, 24, 27 Karyotype complexity is a recently discovered factor for a poor prognosis in CLL in general 4, 28, 29 and in the 17p-subset. 24, 30 In the literature, the cut-off used to define a complex K varies from 3 to 5 abnormalities. 4, 31 In our series, a highly CK (5 abnormalities) was associated with worse TFS, whereas a CK (3 abnormalities) had no clinical impact. This finding suggests that a cut-off of 5 abnormalities is more suitable for identifying 17p-CLL patients with the most aggressive disease. Previous studies of unselected CLL patients have described the poor prognosis of unbalanced translocations. 4, 27, 30, 32, 33 Our present results showed that Utranslocations are also associated with shorter OS in the 17p-CLL subset. Regarding the classical abnormalities detected by FISH in CLL (such as tri12, del13q and del11q), we were surprised to find the same frequency of these aberrations in the 17p-subset as in the whole population of patients with CLL. 1 This suggests that 17p-appears independently, and that none of the other abnormalities promotes its occurrence. However, i(17q) -correlated with trisomy 12 -appears to be an exception.
The 8q24 gain (encompassing the MYC gene) is detected with microarrays in 3-4% of the overall population of patients with CLL, and is independently associated with shorter OS and/or shorter time to first treatment. [34] [35] [36] In the literature, the frequency of 8q24 gain is higher in the 17p-CLL subset and ranges from 9% to 44%. 13, 24, [35] [36] [37] In the present large series, we found an 8q24 gain in 12.5% of patients.
Furthermore, we demonstrated that 8q24 gain is a strong, predictive marker of poor outcome within the 17p-CLL subgroup, and has independent prognostic value for OS. This observation suggests that TP53 deletion and MYC gain act in synergy; the outcome is particularly dismal when both are present. Indeed, the occurrence of both alterations may represent a "double-hit" CLL that is reminiscent of the aggressive, "double-hit," high-grade B-cell lymphomas harboring rearrangements of MYC and BCL2 or BCL6. 38 It is noteworthy that we did not observe any translocation involving MYC in the present series. Given the high frequency of genomic complexity in these patients, 8q24 gain can be missed by karyotyping. In order to validate the clinical significance of this aberration, 17p-CLL patients enrolled in prospective clinical trials should be systematically screened by FISH analysis using a MYC probe.
In conclusion, our data show that patients with 17p-CLL often present CK (3 abnormalities) and highly CK (5 abnormalities), unbalanced translocations, 8q24 gain, and unmutated IGHV. The various abnormalities leading to loss of 17p do not have all the same clinical significance: i(17q) is associated with a shorter OS than the other 17p
aberrations. Furthermore, the presence of additional unbalanced translocations aggravates the outcome. Our results highlight the value of conventional karyotyping for identifying alterations that modulate the prognosis in this aggressive subset of patients. Lastly, 8q24 gain is a strong, independent factor for poor survival; systematic, targeted screening for this abnormality should be considered with a view to better defining the prognosis of patients with 17p-CLL and identifying the very high-risk "double-hit" subgroup.
